Compare AbCellera Biologics Inc (ABCL) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Sana Biotechnology Inc — how do they compare? AbCellera Biologics Inc trades at $7.17 (market cap $2.35B), while Sana Biotechnology Inc trades at $3.94 (market cap $1.15B). The key difference: AbCellera Biologics Inc is far larger — about 2× Sana Biotechnology Inc's market cap, and AbCellera Biologics Inc is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals.
| ABCL | SANA | |
|---|---|---|
Market Cap | $2.35B | $1.15B |
Sector | Health | Health |
52-Week High | $8.12 | $5.92 |
52-Week Low | $2.78 | $2.68 |
Enterprise Value | $1.99B | $1.12B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
SANA Biotechnology trades at $3.97, down 1.0% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative ROE and ROA, while analyst consensus is strongly bullish with 82% buy ratings. Recent news highlights clinical data presentations and a $69 million share sale via an ATM facility in May 2026.
Outlook remains speculative with high investor optimism driven by clinical progress, but significant financial losses and cash burn pose risks. Upside depends on successful drug development, while downside risks include funding needs and trial setbacks. The stock offers high-risk, high-reward potential for biotech investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
